DoseGear research brief
Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24. 2% weight loss at 48 weeks—the highest recorded for obesity medications.
DG Peptide Protocols
Extensively StudiedWeight LossMetabolic
Retatrutide
LY3437943
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Research overview
Mechanism of action
Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Engineered triple-receptor peptide agonist.
What it is researched for
Obesity, type 2 diabetes, and liver-fat research through GLP-1, GIP, and glucagon-receptor agonism.
Research observation window
Cited studies assessed obesity at 48 weeks, diabetes at 36 weeks, and liver fat at 24 weeks.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Starting Dose (Week 1-4) | 0.5mg | Once weekly | SubQ |
| Low Maintenance (Week 4-8) | 1mg | Once weekly | SubQ |
| Escalation (Week 8-12) | 2mg | Once weekly | SubQ |
| Moderate (Week 12-16) | 4mg | Once weekly | SubQ |
| Advanced (Week 16-20) | 8mg | Once weekly | SubQ |
| Maximum Efficacy (Week 20+) | 12mg | Once weekly | SubQ |
Reference cycle
Continuous therapy as prescribed
Reference storage
Reconstituted: 2-8°C, use within 28 days
Safety context
Reported side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
- Heart rate increases—common especially in first 24 weeks
- Appetite suppression
- Mild dehydration
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Severe renal impairment
Scientific references
- 01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Scientific citationTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023). - 02
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
Scientific citationRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. The Lancet (2023). - 03
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Scientific citationTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine (2024). - 04
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Scientific citationStructural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery (2024).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.